Company Announcements

Uniphar plc

Directorate Change

Dublin, London | 30 ​January 2024: Uniphar plc (the "Company" or "Uniphar"), an international diversified healthcare services business addressing the needs of more than 200 multinational pharmaceutical and medical technology manufacturers, is pleased to announce the appointment of Valerie Sick to its Board as an independent non-executive Director, with immediate effect.

Valerie has over 25 years' senior international experience in private and publicly listed pharmaceutical and life science companies in Europe. She has held senior financial and management roles, including managing very diverse operations from a profitability and value creation point of view. Valerie currently serves as Chief Financial Officer of bioMerieux Deutschland GmbH and previous appointments include Director of Finance and Administration of Yves Rocher GmbH and Global Process Owner - Finance for Celesio AG. She is highly experienced in strategic change management and integration across multiple countries and regions to foster growth, with extensive experience in managing multi-stakeholder engagement and strategic decision-making within complex regulated environments at global, regional and national levels. Valerie is fluent in French, German and English and also has a strong interest in climate friendly business models and long-term sustainable business.

Committee Changes

The Company also announces the following non-executive director changes to the composition of the Committees of the Board with immediate effect:

·   Valerie Sick has been appointed to the Nominations, Governance and Sustainability Committee and the Remuneration Committee.

·      Paul Hogan has been appointed as Chair of the Remuneration Committee following the resignation of Jeffrey Berkowitz.

The updated composition of the Committees of the Board will be available on the Company's website: www.uniphar.com.

Maurice Pratt, Chairman of Uniphar plc, commented:

"I am delighted to welcome Valerie to the Board of Uniphar where I believe she will bring extensive commercial and international markets experience and complement the existing skills and expertise of our Board. I, along with the rest of the Board, look forward to working with Valerie as Uniphar seeks to deliver on the significant growth opportunity ahead."

Additional Information:

Valerie Christine Sick (French citizen, aged 52 years) does not hold any ordinary shares or options in the Company. The Company confirms that there is no other information that is required to be disclosed under Schedule 2(g) of the AIM Rules for Companies.

--- ENDS ---

Contact details

About Uniphar plc 

Headquartered in Dublin, Ireland, the Uniphar Group is an international diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology manufacturers across three divisions - Uniphar Pharma, Uniphar Medtech and Uniphar Supply Chain & Retail. The Group is active in Europe, North America, APAC and MENA and delivers to 160+ counties.

The Company's vision is to improve patient access to pharmaco-medical products and treatments by enhancing connectivity between manufacturers and healthcare stakeholders. Uniphar represents a strong combination of scale, growth, and profitability.

Uniphar Supply Chain & Retail

Uniphar Supply Chain and Retail is the leading pharmaceutical wholesaler in Ireland with a growing symbol group offering of retail pharmacies. The Group's strategy for Uniphar Supply Chain and Retail is to grow our wholesale market share, our symbol group network and our own brand, in-licenced and consumer products portfolio.

Uniphar Medtech

Uniphar Medtech is a leading Pan-European medical device distributor and solutions partner. The Group's strategy for Uniphar Medtech is to grow our service offering across Europe and expand our addressable market by serving new specialities and new manufacturers.

Uniphar Pharma

Uniphar Pharma operates a global business with high value services across the lifecycle of a pharmaceutical product. We enable pharma and biotech companies to bring innovative medicines to global markets and provide healthcare professionals with access to medicines they can’t source through traditional channels. Our strategy is to build a leading platform to provide the specialist support and expertise needed to improve access to these medicines.